Notice of Proposed Sale · 144
Jazz Pharmaceuticals plc
JAZZNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Jazz Pharmaceuticals plc
- Issuer CIK
- 0001232524
- SEC file number
- 001-33500
- Phone
- 353-1-634-7800
- Person for whose account securities are to be sold
- Cook Jennifer E.
- Relationships to issuer
- Director
- Street
- FIFTH FLOOR, WATERLOO EXCHANGE
- Street (continued)
- WATERLOO ROAD
- City
- DUBLIN
- State / country code
- L2
- Postal code
- D04 E5W7
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 3,507 | 857,602.00 | 64,914,577 | 08/31/2026 | NASDAQ | ETRADE FINANCIAL CORPORATION |
Broker / market maker — proposed row 1, entry 1
- Name
- ETRADE FINANCIAL CORPORATION
- Street
- 3 EDISON DRIVE
- City
- ALPHARETTA
- State / country code
- GA
- Postal code
- 30005
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| COMMON | 08/28/2026 | RESTRICTED STOCK VESTING | ISSUER | 3,507 | N | 08/28/2026 | Compensation |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/31/2026
- Signed
- /s/Paz Dizon by power of attorney for Jennifer E. Cook
Company context
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare diseases - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.
Current securities
Recent company filings
- Results of Operations and Financial ConditionOct 26, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 9, 2026
- 4 filingOct 5, 2026
- 144 filingOct 1, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 23, 2026